{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-001065","form_type":"8-K/A","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.957778+00:00","generated_at":"2026-05-28T05:28:16.964880+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Lyell closes ImmPACT Bio acquisition; acquired firm had $136.8M deficit, going concern flag","bullets":["ImmPACT Bio's audited FY2023 net loss $58.9M, R&D spend $44.0M, accumulated deficit $136.8M.","Auditors express substantial doubt about ImmPACT's ability to continue as a going concern due to recurring losses and negative cash flows.","ImmPACT had $39.9M cash and equivalents, $1.2M short-term investments, $5.9M property/equipment as of Dec 31, 2023.","Lyell completed acquisition of ImmPACT on Oct 31, 2024; combined pro forma financials filed for FY2023 and nine months ended Sep 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-001065","json":"https://secwatch.observer/filing/0001628280-25-001065.json","markdown":"https://secwatch.observer/filing/0001628280-25-001065.md","text":"https://secwatch.observer/filing/0001628280-25-001065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025001065/0001628280-25-001065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025001065/lyel-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:28:16.964880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}